Thrombotic and hemorrhagic complications of COVID-19 in adults hospitalized in high-income countries compared with those in adults hospitalized in low- and middle-income countries in an international registry


Griffee, Matthew J, Bozza, Patricia T, Reyes, Luis Felipe, Eddington, Devin P, Rosenberger, Dorothea, Merson, Laura, Citarella, Barbara Wanjiru, Fanning, Jonathon P, Alexander, Peta MA, Fraser, John et al (show 1499 more authors) (2023) Thrombotic and hemorrhagic complications of COVID-19 in adults hospitalized in high-income countries compared with those in adults hospitalized in low- and middle-income countries in an international registry. Research and Practice in Thrombosis and Haemostasis, 7 (5). p. 102142.

Access the full-text of this item by clicking on the Open Access link.

Abstract

<h4>Background</h4>COVID-19 has been associated with a broad range of thromboembolic, ischemic, and hemorrhagic complications (coagulopathy complications). Most studies have focused on patients with severe disease from high-income countries (HICs).<h4>Objectives</h4>The main aims were to compare the frequency of coagulopathy complications in developing countries (low- and middle-income countries [LMICs]) with those in HICs, delineate the frequency across a range of treatment levels, and determine associations with in-hospital mortality.<h4>Methods</h4>Adult patients enrolled in an observational, multinational registry, the International Severe Acute Respiratory and Emerging Infections COVID-19 study, between January 1, 2020, and September 15, 2021, met inclusion criteria, including admission to a hospital for laboratory-confirmed, acute COVID-19 and data on complications and survival. The advanced-treatment cohort received care, such as admission to the intensive care unit, mechanical ventilation, or inotropes or vasopressors; the basic-treatment cohort did not receive any of these interventions.<h4>Results</h4>The study population included 495,682 patients from 52 countries, with 63% from LMICs and 85% in the basic treatment cohort. The frequency of coagulopathy complications was higher in HICs (0.76%-3.4%) than in LMICs (0.09%-1.22%). Complications were more frequent in the advanced-treatment cohort than in the basic-treatment cohort. Coagulopathy complications were associated with increased in-hospital mortality (odds ratio, 1.58; 95% CI, 1.52-1.64). The increased mortality associated with these complications was higher in LMICs (58.5%) than in HICs (35.4%). After controlling for coagulopathy complications, treatment intensity, and multiple other factors, the mortality was higher among patients in LMICs than among patients in HICs (odds ratio, 1.45; 95% CI, 1.39-1.51).<h4>Conclusion</h4>In a large, international registry of patients hospitalized for COVID-19, coagulopathy complications were more frequent in HICs than in LMICs (developing countries). Increased mortality associated with coagulopathy complications was of a greater magnitude among patients in LMICs. Additional research is needed regarding timely diagnosis of and intervention for coagulation derangements associated with COVID-19, particularly for limited-resource settings.

Item Type: Article
Uncontrolled Keywords: ISARIC Clinical Characterisation Group
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Infection, Veterinary and Ecological Sciences
Depositing User: Symplectic Admin
Date Deposited: 31 Aug 2023 07:43
Last Modified: 17 Nov 2023 10:32
DOI: 10.1016/j.rpth.2023.102142
Open Access URL: https://doi.org/10.1016/j.rpth.2023.102142
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3172442
Altmetric
Share
CORE (COnnecting REpositories)